Chemoimmunotherapy or BTK inhibition for patients with CLL

Bookmark and Share
Published: 20 Jun 2019
Views: 895
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Dr Othman Al-Sawaf speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about two different treatments for CLL.

He explains that the future of treatment will be to decide when it is necessary to use chemoimmunotherapy or BTK inhibition.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.